193 related articles for article (PubMed ID: 18594817)
1. Topotecan enhances immune clearance of gliomas.
Wei J; DeAngulo G; Sun W; Hussain SF; Vasquez H; Jordan J; Weinberg J; Wolff J; Koshkina N; Heimberger AB
Cancer Immunol Immunother; 2009 Feb; 58(2):259-70. PubMed ID: 18594817
[TBL] [Abstract][Full Text] [Related]
2. Distinct effects of human glioblastoma immunoregulatory molecules programmed cell death ligand-1 (PDL-1) and indoleamine 2,3-dioxygenase (IDO) on tumour-specific T cell functions.
Avril T; Saikali S; Vauleon E; Jary A; Hamlat A; De Tayrac M; Mosser J; Quillien V
J Neuroimmunol; 2010 Aug; 225(1-2):22-33. PubMed ID: 20493562
[TBL] [Abstract][Full Text] [Related]
3. Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the Fas/Fas ligand pathway.
Konkankit VV; Kim W; Koya RC; Eskin A; Dam MA; Nelson S; Ribas A; Liau LM; Prins RM
J Transl Med; 2011 Nov; 9():192. PubMed ID: 22060015
[TBL] [Abstract][Full Text] [Related]
4. Fas-FasL interaction in cytotoxic T cell-mediated vitiligo: The role of lesional expression of tumor necrosis factor-α and interferon-γ in Fas-mediated melanocyte apoptosis.
Jimbo H; Nagai H; Fujiwara S; Shimoura N; Nishigori C
Exp Dermatol; 2020 Jan; 29(1):61-70. PubMed ID: 31675451
[TBL] [Abstract][Full Text] [Related]
5. Expression of Fas/FasL in CD8+ T and CD3+ Foxp3+ Treg cells--relationship with apoptosis of circulating CD8+ T cells in hepatocellular carcinoma patients.
Guo CL; Yang XH; Cheng W; Xu Y; Li JB; Sun YX; Bi YM; Zhang L; Wang QC
Asian Pac J Cancer Prev; 2014; 15(6):2613-8. PubMed ID: 24761872
[TBL] [Abstract][Full Text] [Related]
6. Engineered drug resistant γδ T cells kill glioblastoma cell lines during a chemotherapy challenge: a strategy for combining chemo- and immunotherapy.
Lamb LS; Bowersock J; Dasgupta A; Gillespie GY; Su Y; Johnson A; Spencer HT
PLoS One; 2013; 8(1):e51805. PubMed ID: 23326319
[TBL] [Abstract][Full Text] [Related]
7. Membrane-bound Fas ligand only is essential for Fas-induced apoptosis.
O' Reilly LA; Tai L; Lee L; Kruse EA; Grabow S; Fairlie WD; Haynes NM; Tarlinton DM; Zhang JG; Belz GT; Smyth MJ; Bouillet P; Robb L; Strasser A
Nature; 2009 Oct; 461(7264):659-63. PubMed ID: 19794494
[TBL] [Abstract][Full Text] [Related]
8. Time-dependent cytotoxic drugs selectively cooperate with IL-18 for cancer chemo-immunotherapy.
Alagkiozidis I; Facciabene A; Tsiatas M; Carpenito C; Benencia F; Adams S; Jonak Z; June CH; Powell DJ; Coukos G
J Transl Med; 2011 May; 9():77. PubMed ID: 21609494
[TBL] [Abstract][Full Text] [Related]
9. Lung carcinomas do not induce T-cell apoptosis via the Fas/Fas ligand pathway but down-regulate CD3 epsilon expression.
Prado-Garcia H; Aguilar-Cazares D; Meneses-Flores M; Morales-Fuentes J; Lopez-Gonzalez JS
Cancer Immunol Immunother; 2008 Mar; 57(3):325-36. PubMed ID: 17668204
[TBL] [Abstract][Full Text] [Related]
10. Tumor antigen-specific T cells for immune monitoring of dendritic cell-treated glioblastoma patients.
Müller I; Altherr D; Eyrich M; Flesch B; Friedmann KS; Ketter R; Oertel J; Schwarz EC; Technau A; Urbschat S; Eichler H
Cytotherapy; 2016 Sep; 18(9):1146-61. PubMed ID: 27424145
[TBL] [Abstract][Full Text] [Related]
11. Decitabine Treatment of Glioma-Initiating Cells Enhances Immune Recognition and Killing.
Riccadonna C; Yacoub Maroun C; Vuillefroy de Silly R; Boehler M; Calvo Tardón M; Jueliger S; Taverna P; Barba L; Marinari E; Pellegatta S; Bassoy EY; Martinvalet D; Dietrich PY; Walker PR
PLoS One; 2016; 11(8):e0162105. PubMed ID: 27579489
[TBL] [Abstract][Full Text] [Related]
12. Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis.
Dotti G; Savoldo B; Pule M; Straathof KC; Biagi E; Yvon E; Vigouroux S; Brenner MK; Rooney CM
Blood; 2005 Jun; 105(12):4677-84. PubMed ID: 15713795
[TBL] [Abstract][Full Text] [Related]
13. Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme.
Liu C; Sarkaria JN; Petell CA; Paraskevakou G; Zollman PJ; Schroeder M; Carlson B; Decker PA; Wu W; James CD; Russell SJ; Galanis E
Clin Cancer Res; 2007 Dec; 13(23):7155-65. PubMed ID: 18056196
[TBL] [Abstract][Full Text] [Related]
14. Interferon alpha augments activation-induced T cell death by upregulation of Fas (CD95/APO-1) and Fas ligand expression.
Kaser A; Nagata S; Tilg H
Cytokine; 1999 Oct; 11(10):736-43. PubMed ID: 10525311
[TBL] [Abstract][Full Text] [Related]
15. IFN-γ enhances HOS and U2OS cell lines susceptibility to γδ T cell-mediated killing through the Fas/Fas ligand pathway.
Li Z; Xu Q; Peng H; Cheng R; Sun Z; Ye Z
Int Immunopharmacol; 2011 Apr; 11(4):496-503. PubMed ID: 21238618
[TBL] [Abstract][Full Text] [Related]
16. Ex vivo malignant glioma cells are sensitive to Fas (CD95/APO-1) ligand-mediated apoptosis.
Frei K; Ambar B; Adachi N; Yonekawa Y; Fontana A
J Neuroimmunol; 1998 Jul; 87(1-2):105-13. PubMed ID: 9670851
[TBL] [Abstract][Full Text] [Related]
17. Suppression of FasL expression in tumor cells and preventing TNF-induced apoptosis was better for immune cells survival.
Xu G; Zhang J
J Cancer Res Clin Oncol; 2008 Oct; 134(10):1043-9. PubMed ID: 18461366
[TBL] [Abstract][Full Text] [Related]
18. Fas (Apo-1/CD95) and Fas ligand interaction between gastric cancer cells and immune cells.
Lee TB; Min YD; Lim SC; Kim KJ; Jeon HJ; Choi SM; Choi CH
J Gastroenterol Hepatol; 2002 Jan; 17(1):32-8. PubMed ID: 11895550
[TBL] [Abstract][Full Text] [Related]
19. Splenectomy promotes indirect elimination of intraocular tumors by CD8+ T cells that is associated with IFNγ- and Fas/FasL-dependent activation of intratumoral macrophages.
Miller MR; Mandell JB; Beatty KM; Harvey SA; Rizzo MJ; Previte DM; Thorne SH; McKenna KC
Cancer Immunol Res; 2014 Dec; 2(12):1175-85. PubMed ID: 25248763
[TBL] [Abstract][Full Text] [Related]
20. Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-κB signaling improves the efficacy of immunotherapy in a brain cancer model.
Mineharu Y; Muhammad AK; Yagiz K; Candolfi M; Kroeger KM; Xiong W; Puntel M; Liu C; Levy E; Lugo C; Kocharian A; Allison JP; Curran MA; Lowenstein PR; Castro MG
Neurotherapeutics; 2012 Oct; 9(4):827-43. PubMed ID: 22996231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
